Notably none of the myeloma patients from this study received corticosteroids to counteract the side effects of trametinib, which is currently recommended for the management of toxicities associated with BRAF and MEK inhibitors in melanoma patients [8, 10]. This evidence concerns the gene MAP2K7 and plasma cell myeloma.